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Abstract
Background: HPV is important in a subset of HNSCC. Our meta-analysis determined the clinical characteristics of HPV-
related HNSCC.
Method: Pubmed search terms "HPV" and "HNSCC" were used to identify 34 studies since 1980. We obtained pooled 
adjusted odds ratio (OR) or hazard ratio (HR) using random or fixed-effects model and compared OS depicted in forest 
plot.
Results: A total of 5681 patients were included. The prevalence of HPV+ tumors was 22%, with 86.7% of HPV16+ 
genotype. The OR for HNSCC in HPV16+ patients was 4.44 (95% CI = 2.87-6.02). HPV status was associated with p16 
expression (adj OR = 3.00; 0.90-9.70), and HPV+ tumors were less likely to harbor p53 mutations (adj OR = 0.21; 0.04-
0.38). The HR for death in HPV+ patients was 0.42 (0.27-0.57). HPV+ HNSCC also had a better response to therapy.
Conclusion: HPV+ HNSCC are established as a separate biologic entity. Prospective trials are needed to establish the 
optimal therapy for HPV+ HNSCC.
Introduction
Squamous cell carcinoma of the head and neck (HNSCC)
has an estimated incidence of 35,310 new cases in 2008 in
the United States, with an expected 7590 deaths due to
these cancers. The male to female ratio is approximately
2:1[1]. A recent analysis of the Surveillance, Epidemiology
and End Results (SEER) database showed in younger U.S.
populations (ages 20-44 years) that while there has been
an increase in incidence of tonsillar squamous cell carci-
nomas from 1973 to 2001, the incidence of squamous cell
carcinomas in all other oral and pharyngeal sites
remained constant or decreased[2]. A similar rise in the
incidence of tonsillar squamous cell carcinomas from
1970-2002 has been shown in Sweden and has been asso-
ciated with presence of human papillomavirus (HPV)[3].
For more than 30 years, certain genotypes of "high-risk"
HPVs have been known to be involved in the pathogene-
sis of cervical cancers[4]. Recent studies have implicated
high-risk HPV as a risk factor for HNSCC, independent
of the traditional risk factors, which include tobacco
abuse and ethanol consumption[5-7]. While high-risk
HPV related HNSCC appear to be associated with certain
sexual behaviors, such as oral sex and increasing numbers
of sexual partners, there is a lack of association with
smoking and drinking[5,8]. Clinically, high-risk-HPV
related HNSCC tend to present with lymph node positive
disease and originate from the oropharynx, while histo-
logically these tumors are usually high-grade and can be
described as exhibiting a basaloid morphology [6,9,10].
On a molecular level, the HPV oncoproteins E6 and E7
are implied in tumorigenesis and are known to induce
degradation of the tumor suppressors p53 and pRB,
respectively[11,12]. Another hallmark of HPV related
HNSCC is lack of p53 mutations[13] and p16 protein
overexpression[14-16], a result of loss of transcriptional
repression which occurs as a response to upstream sig-
nals during early tumorigenesis[17]. Studies suggest that
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p16 immunohistochemical expression can function as a
surrogate marker to predict treatment outcome in
HNSCC[14,18].
Recent emerging data indicates that HPV related
HNSCC define a unique population of patients with dis-
tinct biology that likely should be treated separately from
non-HPV related HNSCC[19]. The aims of this meta-
analysis are to consolidate the available data, improve
understanding of the biology of HPV related HNSCC,




To identify articles, we searched the Pubmed database,
combining permutations of the terms ["human papillo-
mavirus" or "HPV] and ["squamous cell carcinoma" or
"cancer"] and ["oropharyngeal" or "oropharynx" or "head
and neck" or "tonsil"]. Additional articles from reference
lists of retrieved articles were reviewed and included as
deemed appropriate. Only articles which solely or sepa-
rately reported on oropharyngeal cancers, were published
from 1980-2008 in English language, and reported HPV
prevalence were considered for inclusion. A total of 34
articles met our inclusion criteria for this meta-analysis.
Statistical Analyses
The presence of study heterogeneity was evaluated using
the Chi-squared based Q test. In order to quantify the
extent (estimated as a percent ranging from 0% to 100%)
of any existing heterogeneity in the meta-analyses, the I2
index was used. Pooled adjusted odds ratios (ORs) for
r i s k  o r  h a z a r d  r a t i o s  ( H R s )  f o r  o v e r a l l  s u r v i v a l  w e r e
obtained using a fixed-effects model (or random-effects
model if needed due to among-study heterogeneity). If
adjusted ORs or HRs were not available, then we used the
same methods as above to pool unadjusted point esti-
mates of risk and survival. Potential sources of publica-
tion bias were detected using a funnel plot which is
simple scatter plots of the effect of interest versus study
size. An asymmetrical funnel plot is indicative of poten-
tial publication bias. If necessary, we omitted studies
prior to the final meta-analytic estimate that were identi-
fied as influential (those outside the allowable bounds
based on the presumption of absence of both heterogene-
ity and publication bias) in the funnel plot. A forest plot
was constructed to visually compare all included studies
with the final pooled statistic. When possible, we also
performed the above meta-analyses for the subset of




A total of 5681 patients in 34 studies were included. To
detect HPV DNA in tumor biopsies, 33 studies used PCR,
and one study used fluorescence in situ hybridization
(FISH). We established a prevalence of HPV among all
head and neck squamous cell carcinoma (HNSCC)
patients of 21.95% (95% CI = 0.21-0.23). The most preva-
lent HPV genotype was HPV-16, representing 86.69%
(95% CI = 0.85-0.89) of all HPV positive tumors (Table 1
and 2). The other two most commonly detected geno-
types were HPV-18 and -33 (data not shown). In the pub-
lications which included information on the subgroup of
oropharyngeal cancers, the prevalence of HPV was 41%
(379 of 925 patients; 95% CI = 0.38-0.44).
HPV as Risk Factor for HNSCC
Overall, positive HPV status (any high-risk genotype)
conferred an increased risk for HNSCC (adjusted OR =
1.83; 95% CI = 1.04-2.62; p < 0.0001) as seen in Figure 1A.
Risk for HNSCC among HPV-16 positive patients was
4.44 times (95% CI = 2.87-6.02; p < 0.0001) that of HPV-
16 negative patients (Figure 1B). As a validation control
for our meta-analysis we assessed the OR of two known
risk factors for HNSCC, tobacco and alcohol consump-
tion[20,21]. We confirmed that heavy smokers and alco-
hol drinkers are at increased risk for HNSCC (smoking
OR = 3.53; 95% CI = 2.69-4.64, p < 0.0001, and alcohol
consumption OR = 4.04; 95% CI = 3.20-5.09, p < 0.0001).
Table 3 shows the association of HPV status with prog-
nostic factors for HNSCC (age, gender, and tumor stage)
and known risk factors for HNSCC (ethanol and tobacco
consumption)
HPV and Survival
Survival was improved in HPV positive patients com-
pared to HPV negative patients (HR = 0.42; 95% CI =
0.27-0.56, p < 0.0001) (Figure 2A). The survival benefit
was similar in HPV-16 positive patients (adjusted HR =
0.41; 95% CI = 0.21-0.61, p < 0.0001). The improved sur-
v i v a l  i n  H P V  p o s i t i v e  p a t i e n t s  w a s  e v e n  m o r e  p r o -
nounced in the subgroup of oropharyngeal cancers
(adjusted HR = 0.40; CI = 0.18-0.61, p < 0.0001) (Figure
2B).
HPV and Treatment Response
A total of ten publications included treatment informa-
tion, but only two reported statistical information on
treatment response to radiotherapy and two reported
efficacy results to chemotherapy/radiotherapy (Table 4).
HPV positive HNSCC have a better response to radio-
therapy compared to HPV negative HNSCC (non-Dayyani et al. Head & Neck Oncology 2010, 2:15
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adjusted OR = 4.07; 95% CI = 1.48-11.18, p = 0.006). Sim-
ilarly, patients who are positive for HPV have an
improved response to concurrent chemo-radiation (non-
adjusted OR = 2.87; 95% CI = 1.29-6.41, p = 0.01).
Correlation with p16 and p53
Several studies reported p16 immunohistochemical
expression in HPV positive HNSCC[22-29]. We found
that HPV status was associated with p16 expression
(adjusted OR = 3.00; 95% CI = 0.90-9.70, p = 0.18), and
HPV positive tumors were less likely to harbor p53 muta-
tions (adjusted OR = 0.21; 95% CI = 0.04-0.38, p = 0.015)
(Table 5). Confirming the notion that p16 expression
might be used as a surrogate for HPV status in HNSCC,
we show that p16 positive HNSCC have reduced hazard
Table 1: HPV Prevalence in 34 trials (N = 5681)






Prevalence HPV16 in 
HPV (%)
Mork rtl, et al. 2001 292 88 30.14% 35 39.77%
D'Souza, et al. 2007 100 40 40.00% 35 87.50%
Gillison, et al. 2000 253 62 24.51% 56 90.32%
Herrero, et al. 2003 1670 56 3.35% 21 37.50%
Smith, et al. 2004 201 46 22.89% 39 84.78%
Braakhuis, et al. 2004 143 24 16.78% 24 100.00%
Fakhry, et al. 2008 96 38 39.58% 36 94.74%
Teman, et al. 2008 105 12 11.43% 0 0.00%
Weinberger, et al. 2006 77 47 61.04% 47 100.00%
Licitra, et al. 2006 90 17 18.89% 17 100.00%
Worden, et al. 2008 66 27 40.91% 27 100.00%
Shindoh, et al. 1995 77 24 31.17% 24 100.00%
Lindel, et al. 2001 99 14 14.14% 11 78.57%
Klussmann, et al. 2001 98 25 25.51% 21 84.00%
Perrone, et al. 2007 77 16 20.78% 16 100.00%
Kutler, et al. 2003 25 21 84.00% 19 90.48%
Smith, et al. 2004 193 38 19.69% 33 86.84%
Baez, et al. 2004 118 52 44.07% 52 100.00%
Dahlgren, et al. 2004 110 12 10.91% 9 75.00%
Hoffmann, et al. 2004 73 28 38.36% 28 100.00%
Slebos, et al. 2006 36 8 22.22% 8 100.00%
Hammarstedt, et al. 2006 203 99 48.77% 86 86.87%
Ragin, et al. 2006 125 30 24.00% 30 100.00%
Reimers, et al. 2007 106 30 28.30% 29 96.67%
Furniss, et al. 2007 486 145 29.84% 145 100.00%
Smith, et al. 2008 301 81 26.91% 77 95.06%
Pintos, et al. 2008 72 14 19.44% 13 92.86%
Charfi, et al. 2008 52 32 61.54% 27 84.38%
Westra, et al. 2008 89 12 13.48% 12 100.00%
Hafkamp, et al. 2008 81 33 40.74% 33 100.00%
Friesland, et al. 2001 34 14 41.18% 14 100.00%
De Petrini, et al. 2006 47 20 42.55% 20 100.00%
Wittekindt, et al. 2005 34 18 52.94% 16 88.89%
Strome, et al. 2002 52 24 46.15% 21 87.50%
5681 1247 21.95% 1081 86.69%Dayyani et al. Head & Neck Oncology 2010, 2:15
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Table 2: Selected characteristics of the 34 studies
N%




Study type Case-control 6 17.65%
Nested Case Control 1 2.94%
Multi-Center Case Control 1 2.94%
Case Series 3 8.82%
Retrospective 20 58.82%
Prospective 3 8.82%
Sample size < 50 5 14.71%
(No. of patients) 50-99 14 41.18%
100-149 7 20.59%
>150 8 23.53%








Method of Detection PCR 33 97.06%
FISH 1 2.94%
Country USA 14 41.18%
Canada 1 2.94%






Norway, Finland, Sweden 1 2.94%
Sweden 3 8.82%
Japan 1 2.94%
International 1 2.94%Dayyani et al. Head & Neck Oncology 2010, 2:15
http://www.headandneckoncology.org/content/2/1/15
Page 5 of 11
Figure 1 Meta-analyses for adjusted odds ratio (OR) for HPV as risk factor for HNSCC Risk for having HNSCC is increased with all types of 
high-risk HPV reported (A) and risk is even more pronounced in cases with HPV-16 infection versus HPV negative controls (B).Dayyani et al. Head & Neck Oncology 2010, 2:15
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ratio for death (adjusted HR = 0.22; 95% CI = 0.02-0.41, p
= 0.028).
Discussion
We have conducted a literature review and large meta-
analysis in HPV related HNSCC to determine the preva-
lence of the disease and assess the ramifications on sur-
vival and associated molecular biomarkers. Given prior
published reports of a higher prevalence of HPV in carci-
nomas of the oropharynx, we concentrated this study on
oropharyngeal carcinomas to enrich and focus the meta-
analysis. Therefore, the number of studies included in our
review is smaller than other previously reported meta-
analyses with different inclusion criteria[30,31]. Several
other meta-analyses on HPV-related HNSCC have been
published before[30-32], but to our knowledge, none of
the prior reports have described within the same report,
the impact of HPV on survival, response to therapy, as
well as the association with molecular markers such as
p16. In addition, our report includes recently published
prospective studies that were not available at the time of
publication of previous meta-analyses. Our data reports
the prevalence of HPV-related HNSCC as 21.95% and is
in accordance with other recently published reports
which estimate the prevalence of HPV at 20-26% [25,30-
32]. As expected, we also confirmed a higher prevalence
of HPV-related tumors in the oropharynx (40.97%) in
agreement with prior studies[31,33]. Virtually all of the
studies included used PCR to detect HPV DNA, a
method with slightly higher sensitivity than in situ
hybridization[31]. The higher sensitivity of the detection
m e t h o d  u s e d  s u g g e s t s  t h a t  t h e  h e r e i n  r e p o r t e d  p r e v a -
lence of HPV associated HNSCC is more likely to reflect
the actual prevalence of HPV as compared to studies
which use less sensitive methods, although given the pau-
city of data regarding the exact specificity of PCR in this
setting does not enable a precise account of the number
of false-positive patients included in these studies. The
relatively wide range of the prevalence of HPV in HNSCC
in the published literature confirms that in addition to
Table 3: Association of HPV status with gender, age, tumor stage, alcohol and tobacco consumption
Demographic # Studies HPV status Smoking status N %
Tobacco 17 HPV+ Ever 1068 55.9
Never 948 44.1
HPV- Ever 2179 74.5
Never 677 25.5
Ethanol 16 HPV+ Ever 1548 66.8
Never 768 33.2
HPV- Ever 2186 75.4
Never 713 24.6
Stage 10* HPV+ I-II 78 26.7
III-IV 214 73.3
HPV- I-II 259 42.8
III-IV 346 57.2
LN Stage 6 HPV+ N0 45 33.5
N1-N3 123 66.5
HPV- N0 204 45.9
N1-N3 240 54.1
Gender 18 HPV+ M 1525 67.8
F7 2 4 3 2 . 2
HPV- M 2010 66.1
F1 0 3 3 3 3 . 9
Median Age 5** HPV+ 55 years
HPV- 60 years
HPV: human papillomavirus; M: male; F: female; LN, lymph node; * 2 studies compared stage I-III vs. stage IV; ** 5 studies reported the median 
age of the subjects.Dayyani et al. Head & Neck Oncology 2010, 2:15
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Figure 2 Overall survival of HPV positive patients compared to HPV negative patients in unselected HNSCC patients (A) and in the sub-
group of patients with oropharyngeal cancers (B).Dayyani et al. Head & Neck Oncology 2010, 2:15
http://www.headandneckoncology.org/content/2/1/15
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geographical differences, the method of HPV detection is
critical for accurate assessment of the HPV status.
In the current study we confirmed the role of p16
immunohistochemical expression as a surrogate marker
for HPV infection in HNSCC, which is not only positively
associated with HPV infection but also predicts for an
improved survival outcome[14,28,29]. The HPV onco-
protein E7 is known to induce degradation of pRb, which
in turn leads to upregulation of p16[34]. Therefore, over-
expression of p16 is considered to be one of the molecular
hallmarks of HPV positive HNSCC[4,23,35,36] and has
recently been shown to identify HPV related oropharyn-
geal cancers with favorable outcomes[16]. In a recent
prospective trial, an analysis of tumor tissue (n = 323) col-
lected from RTOG 0129 using HPV in situ hybridization
(ISH) and p16 immunohistochemistry (IHC) demon-
strated that p16 correlated well with HPV ISH with 96%
of HPV positive tumors also expressing p16[19]. An addi-
tional 19% (n = 22) were p16 positive but HPV negative.
Both HPV and p16 positive status predicted for an
improved survival. This finding of p16 IHC positive
tumors identifying more patients than HPV ISH was also
seen in an additional study called HeadStart[37]. This
trial compared HPV ISH and p16 IHC on tumor speci-
mens from two arms of therapy, cisplatin-radiation versus
cisplatin-tirapazamine-radiation, and suggested that p16
IHC may identify a higher percentage of HPV positive
tumors than the HPV ISH assay. Given the debate regard-
ing the best detection method for HPV[38], our data from
the meta-analysis confirms that p16 IHC could be used in
future in prospective trials as a reliable surrogate marker
for HPV related HNSCC[19,37,39]. As the above two
recent studies (RTOG and HeadStart) have only been
reported in abstract form, we did not include them in our
meta-analysis.
As HPV-related oropharyngeal cancers are reported to
be rising in incidence[2,3], it is important to consider
treating this disease as a unique entity. Our data in con-
gruence with other studies indicate that HPV positive
HNSCC have a distinct biology, and are more responsive
to treatment with radiotherapy and chemotherapy. In
addition to treatment response, we and others have
shown an improved survival in patients with HPV posi-
tive HNSCC, with a 60% lower risk of death. Our survival
results are slightly different from other reports; a recent
meta-analysis reported a death hazard ratio of 0.85. This
discrepancy can be explained by the addition of the
recent prospective trials[10,14,40,41] in our analysis
which were not included in prior reports. Our meta-anal-
ysis also confirms a better response to treatment in HPV
Table 4: Treatment type and country of origin of studies that reported treatment information
Author, Year Type of Treatment Country
Fakhry, et al. 2008 CTX followed by Chemo-XRT United States
Weinberger, et al. 2006 XRT ± surgery United States
Worden, et al. 2008 CTX followed by Chemo-XRT or XRT/surgery United States
Lindel, et al. 2001 XRT Switzerland
Dahlgren, et al. 2004 XRT Sweden
Smith, et al. 2008 XRT ± surgery United States
Hafkamp, et al. 2008 CTX ± XRT ± surgery Netherlands
Friesland, et al. 2001 XRT Sweden
CTX: Chemotherapy; XRT: Radiotherapy; Chemo-XRT: concurrent chemo-radiation
Table 5: Meta-analyses of association between p53 mutations, p16 and HPV
Before outlier exclusion After outlier exclusion
Outcome Marker No. of Studies Adjusted OR (95% 
CI)
No. of Studies Adjusted OR (95% 
CI)
HPV positive p53 (mutated) 4 0.21(0.04-0.38) 4 0.21(0.04-0.38)
P = 0.015
HPV positive p16 2 5.02(1.08-8.97) 1 3.00(0.90-9.70)
IHC p = 0.181Dayyani et al. Head & Neck Oncology 2010, 2:15
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positive HNSCC in accordance with recently published
trials[10,14,39,41,42]. Recent reports have highlighted the
importance of the negative influence of smoking on prog-
nosis within HPV positive HNSCC[19,43], and future
studies are required to examine this relationship in a pro-
spective manner.
There are several limitations inherent to our methodol-
ogy, which was based on literature review, not individual
patient data. While the total number of patients included
in our meta-analysis is large, for many specific associa-
tions the number of the studies that actually could be
combined to provide information is relatively small. This
is a limitation which unfortunately cannot be overcome
without access to primary data from all included publica-
tions. Also, there is overlap of the same patient series
included in multiple reports. We tried to account for this
fact as much as possible by reviewing the author list and
institution of each paper and including only the largest
study if several were apparently from the same group.
Finally, given the heterogeneity of the kinds of studies our
meta-analysis was based on, it is difficult to combine con-
clusions drawn, e.g. assessing HPV as risk factor for
HNSCC from case series, retrospective and prospective
trials. There is no valid formulation to give adequate
weight to the results of each kind of the studies men-
tioned. In spite of the limitations inherent to this type of a
meta-analysis, our results are in keeping with published
literature and our current understanding of the natural
biology of HPV-related HNSCC. We also performed as a
validation control a meta-analysis for the established
HNSCC risk factors smoking and alcohol consumption.
Our results confirmed prior published results [20,21].
For the future, there is a need for randomized prospec-
tive data to identify the optimal treatment for patients
based on the tumor's HPV status and to also develop
potential prevention programs. First, given the apparent
improved response to current treatment modalities,
patients with HPV-related HNSCC may be able to receive
adequate curative intent therapy from a reduction in radi-
ation or chemotherapy dose. These issues will require
future clinical trial designs to either prospectively stratify
patients by HPV status or to conduct trials which are
dedicated to HPV positive HNSCC. In addition, it is nec-
essary to determine the best method of detecting the
HPV status and validate whether p16 overexpression
should be utilized as a surrogate or in conjunction with
direct HPV testing. Given the etiologic involvement of
the HPV oncoproteins E6 and E7 during carcinogenesis
of these tumors[44], it is also conceivable that interven-
tion with anti-viral drugs may enhance sensitivity of these
tumors to cytotoxic drugs, with the goal of reducing the
required dose of chemotherapeutic agents and the associ-
ated side effects. Exploratory biomarker studies will be
needed to identify prognostic and predictive markers in
order to tailor specific therapies (such as biologic agents)
to the biology of the patients' malignancy, resulting in
better tolerability of treatment with improved outcomes.
The issue of preventing HPV associated HNSCC from
occurring requires investigation as well. Two recently
approved vaccines to prevent HPV-related cervical can-
cers[45,46] cover the two serotypes that are most preva-
lent in HPV-related HNSCC (HPV-16 and 18). In the
context of the findings of our study, it is conceivable that
extending vaccination to both sexes would prevent a sig-
nificant number of future oropharyngeal cancers in both
men and women. Also, the hypothesized benefits of
HPV-vaccination would potentially include a reduced
incidence of other HPV-related cancers (i.e. vulvar, vagi-
nal, anal, and penile cancers)[47]. On the other hand, a
recent study showed that vaccination of males on a popu-
lation basis might not be cost-effective[48]. Even in
women, controversy exists regarding the maximum age at
which the HPV-vaccine should be given, and a recent
simulation model suggested that vaccination beyond 30
years of age might also not be cost-effective[49]. Given all
these uncertainties, it will therefore be of great impor-
tance to assess in prospective trials that include both
sexes the efficacy of these vaccines to prevent HPV-
related HNSCC.
Conclusions
HPV-related HNSCC comprise about 25% of all HNSCC.
They are predominantly tumors of the oropharynx, and
exhibit a separate biologic behavior including improved
response to (chemo)-radiation and survival compared to
HPV-negative HNSCC. The optimal therapy for this sub-
set of patients remains unclear, but the growing data sup-
ports the theory that this subset of patients should be
treated differently than HPV negative patients. In addi-
tion to this avenue of clinical research, identifying periph-
eral surrogate biomarkers and possible screening and
prevention methods is an important field of future inves-
tigation.
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